A+ A A- Skip to main content

Asian Paints

2225.8 60.60

Cipla

1195.9 -28.30

Eicher Motors

6825.5 239.50

Nestle India

1180.8 6.00

Grasim Inds

2592.8 35.10

Hindalco Inds.

904.6 20.15

Hind. Unilever

2064.7 9.50

ITC

291.7 4.00

Trent

3526.5 230.70

Larsen & Toubro

3607.5 103.40

M & M

3031.5 76.80

Reliance Industries

1369.2 25.30

Tata Consumer

1023.8 9.00

Tata Motors PVeh

302.95 6.75

Tata Steel

194.6 2.74

Wipro

191.18 3.54

Apollo Hospitals

7305.5 -113.50

Dr Reddy's Labs

1209.6 -45.30

Titan Company

4065.5 114.10

SBI

1017.8 38.40

Shriram Finance

900.55 28.45

Bharat Electron

418.7 18.05

Kotak Mah. Bank

356.05 2.65

Infosys

1275.7 25.10

Bajaj Finance

817.3 15.75

Adani Enterp.

1842.5 83.70

Sun Pharma.Inds.

1728.5 -28.70

JSW Steel

1140.4 17.90

HDFC Bank

742.25 10.70

TCS

2408.2 49.30

ICICI Bank

1212.7 6.80

Power Grid Corpn

292.8 -3.30

Maruti Suzuki

12509 203.00

Axis Bank

1193.1 31.80

HCL Technologies

1354.4 12.80

O N G C

288.05 3.40

NTPC

364.65 -6.00

Coal India

449.4 -1.05

Bharti Airtel

1781.9 -0.50

Tech Mahindra

1404.5 20.50

Jio Financial

231.93 7.83

Adani Ports

1385.4 72.80

HDFC Life Insur.

572.95 -17.65

SBI Life Insuran

1790.5 13.20

Max Healthcare

958.9 -3.40

UltraTech Cem.

10714 -31.00

Bajaj Auto

8895.5 114.00

Bajaj Finserv

1647 15.20

Interglobe Aviat

4180.8 237.30

Eternal

236.52 7.54

Corporate News - Detailed News Back
Lupin launches innovative fixed dose triple combination drug 'Vilfuro-G?' in India
23-Nov-23   11:37 Hrs IST
Lupin announced that it has launched the world's first fixed-dose triple combination drug (FDC) under the brand name Vilfuro-G? for the effective management of chronic obstructive pulmonary disease (COPD) in India. This milestone follows the approval granted by the Drug Controller General of India for the Dry Powder Inhaler (DPI) product.

Lupin Vilfuro-G? is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide, for the long-term management and treatment of moderate to severe COPD. The product is available in a single-strength fixed dose, with a recommended once-daily dosage. This therapeutic innovation by Lupin brings hope to more than 37 million individuals struggling with COPD in India, a condition that ranks among the leading causes of death and disability in the nation.

Powered by Capital Market - Live News


DJIA 46363.90
1126.75 2.49%
S&P 500 6550.24
185.52 2.91%
HANG SENG 25294.04
505.89 2.04%
NIKKEI 225 53589.67
2525.95 4.95%
FTSE 100 10364.79
188.34 1.85%
NIFTY 22679.40
348.00 1.56%
×
Ask Your Question
close
refresh